Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 116 Carcinoma, Non-Small-Cell Lung 101 Carcinoma, Renal Cell 67 Colorectal Neoplasms 46 Neoplasm Metastasis 40 Squamous Cell Carcinoma of Head and Neck 38 Carcinoma, Hepatocellular 38 Neoplasms 35 Lung Neoplasms 34 Stomach Neoplasms 33 Urinary Bladder Neoplasms 22 Hodgkin Disease 20 Carcinoma, Transitional Cell 20 Brain Neoplasms 20 Pancreatic Neoplasms 18 Ovarian Neoplasms 18 Prostatic Neoplasms 16 Head and Neck Neoplasms 16 Colonic Neoplasms 16 Skin Neoplasms 15 Sarcoma 14 Glioblastoma 14 Adenocarcinoma Of Esophagus 14 Triple Negative Breast Neoplasms 13 Carcinoma, Merkel Cell 13 Small Cell Lung Carcinoma 12 Rectal Neoplasms 12 Esophageal Neoplasms 12 Breast Neoplasms 12 Uveal Melanoma 11

Interventions

pembrolizumab 4 Cyclophosphamide 4 Radiotherapy 3 Cisplatin 3 fludarabine 2 Doxorubicin 2 Carboplatin 2 zimberelimab 1 olaparib 1 lenvatinib 1 envafolimab 1 avelumab 1 Thymectomy 1 Taxes 1 Sunitinib 1 Robotic Surgical Procedures 1 Ramucirumab 1 Radiotherapy, Adjuvant 1 Paclitaxel 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Etoposide 1 Drug Therapy 1 Chemoradiotherapy 1 Cetuximab 1 AP 1903 reagent 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × Nivolumab × 1 year × Clear all

NCT03134118 2026-05-15

NIVOTHYM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡